Daniel Taheri, MD
Dermatology · Los Angeles, CANPI 1992774681
Payments from drug & device makers
Across 108 payments — averaging $113.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$10K
- Merz North America, Inc.$969
- AbbVie$716
- Galderma Laboratories, L.p.$177
- Regeneron Healthcare Solutions, Inc.$149
- Novartis$111
- plus $384 from 11 others
What the payments were for
- Consulting fees$7,80064%
- Travel & lodging$1,49812%
- Food & beverage$2,95024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 12 | $9,741 |
| Merz North America, Inc. | 15 | $969 |
| AbbVie(2 entities) | 42 | $716 |
| Galderma Laboratories, L.p. | 12 | $177 |
| Regeneron Healthcare Solutions, Inc. | 2 | $149 |
| Novartis | 5 | $111 |
| Johnson & Johnson | 4 | $81 |
| Pfizer | 4 | $73 |
| Sensus Healthcare, Inc. | 2 | $46 |
| VYNE Pharmaceuticals Inc. | 2 | $36 |
| Biofrontera Inc. | 1 | $31 |
| Amgen | 1 | $30 |
| Tactile Systems Technology Inc | 2 | $26 |
| DUSA Pharmaceuticals, Inc. | 1 | $20 |
| Misonix Inc | 1 | $15 |
| Prugen, Inc. Pharmaceuticals | 1 | $13 |
| LEO Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,248 in reported general payments places this provider in the 80th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 42 | $95,101 |
| Clobetasol Propionate | 40 | $2,613 |
| Fluocinonide | 26 | $2,077 |
| Ketoconazole | 38 | $839 |
| Desonide | 12 | $695 |
| Doxycycline Hyclate | 16 | $424 |
| Clindamycin Phosphate | 12 | $394 |
| Cephalexin | 53 | $257 |
| Mupirocin | 34 | $174 |
| Minocycline Hcl | 18 | $111 |
| Minoxidil | 17 | $96 |
| Hydrocortisone | 13 | $95 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Los Angeles
- Howard SofenLos Angeles$16.1M
- April ArmstrongLos Angeles$6.2M
- Christopher HoLos Angeles$2M
- Pearl GrimesLos Angeles$1.6M
- Jonathan CotliarLos Angeles$1.4M
- Jennifer HsiaoLos Angeles$1.1M
- Derek JonesLos Angeles$1.1M
- Roger LoLos Angeles$727K
- Vivian LaquerIrvine$20.9M
- Raja SivamaniSacramento$11.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.